MedTrace Logo

Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

NCT05410301 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-04-21

No results posted yet for this study

Summary

A prospective, open label, single-center, early feasibility trial will be conducted to assess the safety and feasibility of a home-based Static Magnetic and Electric (sBE) device applied for 8 hours/day during sleep in adult participants with recurrent glioblastoma (rGBM) at their first relapse.

Conditions

Interventions

DEVICE

Static Magnetic and Electric (sBE) device

Home-based Static Magnetic and Electric (sBE) device that is slept in

DRUG

Lomustine

Chemotherapy drug

DRUG

Bevacizumab

Chemotherapy and targeted therapy drug

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Varun Monga, MD

    lead OTHER

Principal Investigators

  • Varun Monga, MD · University of Iowa Hospitals & Clinics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410301 on ClinicalTrials.gov